valu usd unless otherwis note
view continu show momentum underli busi
illustr strong pharma medic devic
growth result manag rais revenu ep forecast
reiter outperform rate price target
jnj ww revenu grew y/i led pharma jnj ww revenu
increas organ
estim upsid mostli pharma segment
vs rbce grew y/i intern pharma
revenu increas driven darzalex stelara
imbruvica edur us pharma revenu increas
y/i neg impact gener competit
zytiga impact us growth xarelto
flat us driven increas volum off-set legisl
chang medicar part donut hole rebat remicad
decreas due increas discount share loss
biosimilar off-set strong perform tremfya
invega imbruvica darzalex
jnj medic devic revenu exepect jnj
world-wide medic devic sale fce exclud
acquisitions/divestitur world-wide medic devic busi
y/i jnj ww knee revenu y/i rbce
believ lost less world-wide knee market share
vs maintain gain world-wide hip share
ww hip revenu y/i rbce jnj electrophysiolog
busi grew y/i driven continu double-digit y/i
afib procedur growth strong contact forc sens cathet
diagnost cathet sale final surgeri perform came better
expect due primarili specialti surgeri
print show underli fundament continu improv yet
litig remain overhang recent articl wsj suggest
three drug distributor discuss
state attorney gener local govern global opioid
settlement separ articl also point ok judg
rule verdict may reduc verdict
believ settlement may pitch
global settlement addit clariti opioid liabil would
repres potenti posit catalyst share
adjust estim reiter pt revenu
estim increas howev lower ep
account higher spend vs prior
higher tax rate vs prior forecast
mid-single-digit pharma growth low-to-mid-single-digit growth
medic devic consum pt remain
price prior trade day market close estimate unless otherwis note
forecast ww organ revenu growth
forecast take account signific
sale eros zytiga besid biosimilar competit
remicad gener eros brand base
prescript trend key growth brand strength
outsid medic devic
gradual improv medic devic believ
scope upward revis guidanc
mega-blockbust
contribut new product main growth driver
segment mega-blockbust
brand ww annual peak sale potenti billion
stelara imbruvica darzalex xarelto invega
sustenna/trinza estim ww sale
mega-blockbust increas high-teen led
stelara imbruvica darzalex new brand
tremfya erleada contribut billion
sale estim recent approv spravato esketamin
balversa erdafitnib ad two new growth
driver segment
set goal grow market
medic devic jnj end-market annual
growth rate around certain end-market
vision electrophysiolog advanc surgeri
grow line market compens slower-
qualiti improv adapt busi
model chang environ element
strategi achiev goal
bloomberg capit market estim upside/downside/target
arriv price target use sum-of-the-
part sotp price-to-earnings analysi valu three segment
medic devic consum separ
base peer group multipl base case estim
assum mid-single-digit oper growth
exclud zytiga margin expans share buyback
price target impli price-to-earnings multipl
ep estim y/i
 stronger growth medic
devic segment lift jnj revenu growth basi point
vs base case estim restructur portfolio
ration lead superior oper leverag rel
base case scenario pharmaceut price rhetor
lead legisl chang govern
negoti price pharma compani upsid
scenario impli price-to-earnings multipl ep estim
y/i assumpt
aggress eros remicad zytiga
brand biosimilar gener competit lack
 depress revenu growth neg
downward pressur jnj multipl downsid
scenario impli price-to-earnings multipl y/i
ep estim assumpt
price target base sum-of-the-part sotp analysi target price-to-earnings
multipl base year medic devic consum segment
respect correspond peer group multipl
assign premium segment superior
underli growth outlook rel market growth estim next three year
pharmaceut segment contribut toward price target medic devic
consum price target impli blend price-to-earnings multipl ep estim
y/i slight discount price-to-earnings ntm averag price target
support outperform rate share
risk rate price target
face risk typic global diversifi healthcar compani includ
slump navig fda may risk price target rate
johnson johnson one largest diversifi healthcar busi
world oper compani encompass broad rang product
across healthcar field compani world-wide busi divid three main
segment medic devic diagnost sale
